This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index CI
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer MT
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins CI
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating MT
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Microsoft Kicks -2- DJ
C4 Therapeutics Shares Jump After JPMorgan Upgrade MT
JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6 MT
Transcript : C4 Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : Dow Set For New -2- DJ
Top Midday Gainers MT
Sector Update: Health Care Stocks Flat Premarket Wednesday MT
Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2 MT
C4 Therapeutics Flags 'Promising' Early Data in Trial of Multiple Myeloma, Non-Hodgkin's Lymphomas Treatment MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma CI
Sector Update: Health Care MT
Top Midday Gainers MT
Transcript : C4 Therapeutics, Inc. - Special Call
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1% MT
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket MT
Chart C4 Therapeutics, Inc.
More charts
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.86 USD
Average target price
17.22 USD
Spread / Average Target
+151.05%
Consensus
  1. Stock Market
  2. Equities
  3. CCCC Stock
  4. News C4 Therapeutics, Inc.
  5. C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer